Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$3.6 million.

  • Lineage Cell Therapeutics' Free Cash Flow rose 38.50% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.9 million, marking a year-over-year increase of 9.46%. This contributed to the annual value of -$23.7 million for FY2024, which is 19.09% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Free Cash Flow is -$3.6 million, which was up 34.67% from -$5.6 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Free Cash Flow's 5-year high stood at $21.9 million during Q1 2022, with a 5-year trough of -$11.4 million in Q1 2023.
  • Its 3-year average for Free Cash Flow is -$6.1 million, with a median of -$5.8 million in 2024.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 393.99% in 2022, then plummeted by 152.29% in 2023.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Free Cash Flow stood at -$6.0 million in 2021, then plummeted by 37.68% to -$8.3 million in 2022, then grew by 26.27% to -$6.1 million in 2023, then decreased by 9.84% to -$6.7 million in 2024, then soared by 38.50% to -$3.6 million in 2025.
  • Its Free Cash Flow stands at -$3.6 million for Q3 2025, versus -$5.6 million for Q2 2025 and -$5.0 million for Q1 2025.